Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Some of the gains have come as the broader market has rallied, but there are signs fundamental factors are at play as well.

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the ...

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

Miky Lee, producer behind Oscar-winning 'Parasite', is set to be honored with the Ellis Island Medal of Honor. She joins ...